Skip to main content

Published locations for Risk for MACEs higher in new users of IL12/23 and IL17 inhibitors vs TNF inhibitors in PsA

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Risk for MACEs higher in new users of IL12/23 and IL17 inhibitors vs TNF inhibitors in PsA

User login

  • Reset your password
  • /content/risk-maces-higher-new-users-il12/23-and-il17-inhibitors-vs-tnf-inhibitors-psa
  • /rheumatology/article/243397/psoriatic-arthritis/risk-maces-higher-new-users-il12/23-and-il17
  • /psoriatic-arthritis-icymi/article/243397/psoriatic-arthritis/risk-maces-higher-new-users-il12/23-and